[Skip to Content]

Upstate Active Clinical Trials

Study Title:

NRG-LU007: RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial

What is the purpose of the study? (in Layman's terms, please describe the study)

Can we extend the time without your extensive small cell lung cancer growing or spreading by adding radiation therapy to the usual treatment for this type of cancer (an immunotherapy drug called atezolizumab)?

Upstate Institutional Review Board (IRB) Number:

1667413

Study/Protocol ID:

NRG-LU007

Study Phase:

II/III

Patient Age Group:

Adults

Principal Investigator:

Michael D Mix, MD

What is involved if I participate?

  • How long is the study?
    After you finish chemotherapy and Atezolizumab, you will either get Atezolizumab alone until your disease gets worse or the side effects become too severe, or you will get Atezolizumab with radiation therapy during the first 5 weeks of treatment, then Atezolizumab alone until your disease gets worse or the side effects become too severe.
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Please contact the CRA for more information.

Where will the study take place?

SUNY Upstate Cancer Center -all procedures
Verona Cancer Center - all procedures
Oswego - all procedures
Hill Medical Center - RT

Other Information:

Please contact the CRA for more information

ClinicalTrials.Gov ID:

NCT04402788

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Erin Bingham, CCRP
Phone: 315-464-3603
Email: binghame@upstate.edu

Return to Previous Page || Search Again

Top